Research programme: liposomal cytotoxic compounds - TOT Biopharm

Drug Profile

Research programme: liposomal cytotoxic compounds - TOT Biopharm

Alternative Names: TLD 208; TOT 201; TOT 202; TOT 203

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator TOT Biopharm
  • Class Antineoplastics
  • Mechanism of Action Cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 25 Oct 2016 Preclinical trials in Cancer in China (unspecified route) (TOT Biopharm pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in China
  • 16 Jul 2016 No recent reports of development identified for research development in Colorectal-cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top